| Sep 8 |
Vaxcyte's Broad-Spectrum Pneumococcal Vaccines Poised For Market Dominance By 2027
|
| Sep 6 |
Vaxcyte Announces Closing of $1.5 Billion Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
|
| Sep 6 |
Vaxcyte: Stunning PCV Data Readout Suggests Vaccine Maker Is A Strong Buy
|
| Sep 6 |
Obesity drug startup raises $67M; Vor’s ‘shielded transplant’ shows promise
|
| Sep 5 |
Vaxcyte prices $1.3B equity offering
|
| Sep 5 |
Vaxcyte Announces Pricing of $1.3 Billion Public Offering
|
| Sep 4 |
Vaxcyte Stock Hits Record High on Pneumococcal Vaccine Study Results
|
| Sep 4 |
Company News for Sep 4, 2024
|
| Sep 3 |
Vaccine Maker Raising $1 Billion Leads Post-Holiday Share Sales
|
| Sep 3 |
Vaxcyte commences proposed public offering of common stock & pre-funded warrants
|
